Company intelligence / Profile preview

TearRestore

Ownership: Private
Development stage: Commercial

Overview

TearRestore has clinically validated products for dry eye disease, including the Thermal Mask, which improved tear break-up time by 90% and reduced symptoms by 51% in an academic study. Products are available over-the-counter and are positioned as innovative alternatives to artificial tears.

Therapeutic areas: Ophthalmology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Target (retail partnership for commercial distribution)Target Optical

Beyond the preview

Go deeper on TearRestore.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TearRestore.

Explore the full profile